Vevo LAZRThis product is being discontinued.
Dear Valued Customer,
At FUJIFILM VisualSonics Inc. (FF-VSI), we are committed to providing the highest quality products and services to our customers. The Vevo LAZR Imaging System is being discontinued. All technology products eventually reach the end of their useful life, requiring a difficult decision to discontinue them. Product discontinuation is a part of the cycle that drives new technology and product innovation. Today, we continue to offer our customers the robust Vevo 3100 Ultrasound and the Vevo LAZR-X Multi-modal (ultrasound and photoacoustics) Imaging Solutions for your preclinical imaging needs. See product retirement information.
The Vevo LAZR system is a versatile multi-modality imaging platform based on the Vevo 2100 which combines high resolution anatomical visualization with functional data such as oxygen saturation, hemodynamics and biomarker microdistribution. This fast, non-invasive, real-time modality is perfect for small animal imaging where pathologies and response to treatment can be monitored longitudinally for more robust, publishable data. The system features:
- Oncology - Hypoxia, response to therapy
- Molecular biology - Biomarker distribution, probe development
- Neurobiology - Stroke, blood-brain barrier disruption
- Drug development - Microdistribution, pharmacokinetics
Learn about the NEW Vevo LAZR-X! Our most advanced multi-modal platform combining high frequency ultrasound and photoacoustics to date.
Featured applications related to the Vevo LAZR
Watch webinars, presentations or videos related to the Vevo LAZR below.
Learn more about the Vevo LAZR by attending one of our courses, webinars or events.
Publications related to the Vevo LAZR
Biomedical photoacoustics beyond thermal expansion using triggered nanodroplet vaporization for contrast-enhanced imaging
Development and Validation of a Combined Photoacoustic Micro- Ultrasound System for In Vivo Oxygen Saturation Estimation
Thank you for your patience. Your search results are loading.